Analysis of Aurobindo Pharma 2021
Aurobindo Pharma is a well-known pharmaceutical company based in Hyderabad, India. The company is known for its products in the areas of antibiotics, gastroenterological, anti-diabetics, cardiovascular system, central nervous system, antiretrovirals, and anti-allergics. The company is also active in the manufacturing of vaccines and offers other services like fermentation development, the development of various biochemical processes, and many others.
Since the beginning of the COVID-19 pandemic, Aurobindo Pharma has been actively developing multiple vaccines against the novel coronavirus. The company has also entered into an exclusive licensing agreement with the US-based company Covaxx to develop, commercialize, and manufacture the first peptide-based vaccine against COVID-19.
Aurobindo Pharma is also one of the biggest generic drug companies globally, having a presence in over 150 countries. The company is the seventh-largest generic company globally in terms of sales, and it claims to be the second-largest listed Indian pharmaceutical company in terms of revenues.
Aruvian Research presents Analysis of Aurobindo Pharma. A complete and comprehensive analysis of Aurobindo Pharma includes an overview of the industry the company operates in and the impact of the COVID-19 pandemic on the pharmaceutical industry in India.
Company analysis from Aruvian includes a history of Aurobindo Pharma, a business segment analysis of the segments Aurobindo Pharma operates through, a look at the organization structure of the company, its product pipeline, investment analysis, a geographical operating segments analysis, and how Aurobindo Pharma has been working at the forefront during the COVID-19 pandemic are all analyzed comprehensively in this report.
The major competitors of Aurobindo Pharma, namely Dr. Reddy's Laboratories Limited, Cipla Limited, Pfizer, and Sun Pharmaceutical are analyzed through a company profile, in-depth business segment analysis, a financial analysis, and SWOT analysis. An economic analysis of Aurobindo Pharma is also presented through ratio analysis, profit and loss analysis, presentation of the company balance sheet, and much more.
A SWOT Framework Analysis of Aurobindo Pharma completes this in-depth company analysis.
Since the beginning of the COVID-19 pandemic, Aurobindo Pharma has been actively developing multiple vaccines against the novel coronavirus. The company has also entered into an exclusive licensing agreement with the US-based company Covaxx to develop, commercialize, and manufacture the first peptide-based vaccine against COVID-19.
Aurobindo Pharma is also one of the biggest generic drug companies globally, having a presence in over 150 countries. The company is the seventh-largest generic company globally in terms of sales, and it claims to be the second-largest listed Indian pharmaceutical company in terms of revenues.
Aruvian Research presents Analysis of Aurobindo Pharma. A complete and comprehensive analysis of Aurobindo Pharma includes an overview of the industry the company operates in and the impact of the COVID-19 pandemic on the pharmaceutical industry in India.
Company analysis from Aruvian includes a history of Aurobindo Pharma, a business segment analysis of the segments Aurobindo Pharma operates through, a look at the organization structure of the company, its product pipeline, investment analysis, a geographical operating segments analysis, and how Aurobindo Pharma has been working at the forefront during the COVID-19 pandemic are all analyzed comprehensively in this report.
The major competitors of Aurobindo Pharma, namely Dr. Reddy's Laboratories Limited, Cipla Limited, Pfizer, and Sun Pharmaceutical are analyzed through a company profile, in-depth business segment analysis, a financial analysis, and SWOT analysis. An economic analysis of Aurobindo Pharma is also presented through ratio analysis, profit and loss analysis, presentation of the company balance sheet, and much more.
A SWOT Framework Analysis of Aurobindo Pharma completes this in-depth company analysis.
A. EXECUTIVE SUMMARY
B. LOOKING AT THE INDUSTRY
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impact of Covid-19 on the Pharmaceutical Industry
C. INDUSTRY SWOT ANALYSIS
C.1 Strengths to Build Upon
C.2 Weaknesses to Overcome
C.3 Opportunities to Exploit
C.4 Threats to Overcome
D. LOOKING AT AUROBINDO PHARMA
D.1 Company Profile
D.2 History of the Company
D.3 Aurobindo Pharma and the COVID-19 Pandemic
D.4 Ownership Pattern in the Company
D.5 Organizational Divisions
D.6 Profiling the Key Executives
D.7 Products & Services
E. AUROBINDO PHARMA: LOOKING AT BUSINESS
E.1 Business Segments
E.2 Company Strategy
E.3 Investment Analysis
E.4 Product Pipeline
E.5 Geographical Segments
E.6 Company Subsidiaries
F. AUROBINDO PHARMA: SWOT FRAMEWORK ANALYSIS
F.1 Strengths to Build Upon
F.2 Weaknesses to Overcome
F.3 Opportunities to Exploit
F.4 Threats to Overcome
G. PROFILING THE COMPETITION
G.1 Dr. Reddy's Laboratories Limited
##G.1.1 Corporate Profile
##G.1.2 Business Segment Analysis
##G.1.3 Financial Analysis
##G.1.4 SWOT Analysis
G.2 Cipla Limited
##G.2.1 Corporate Analysis
##G.2.2 Business Segment Analysis
##G.2.3 Financial Analysis
##G.2.4 SWOT Analysis
G.3 Pfizer
##G.3.1 Corporate Analysis
##G.3.2 Business Segment Analysis
##G.3.3 Financial Analysis
##G.3.4 SWOT Analysis
G.4 Sun Pharmaceutical Industries
H. AUROBINDO PHARMA: FINANCIAL ANALYSIS
H.1 Current Financials
H.2 Balance Sheet
H.3 Profit & Loss Statement
H.4 Ratio Analysis
##H.4.1 Annual Ratios
##H.4.2 Interim Ratios
##H.4.2 Capital Market Ratios
##H.4.3 Liquidity Ratios
I. GLOSSARY OF TERMS
B. LOOKING AT THE INDUSTRY
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impact of Covid-19 on the Pharmaceutical Industry
C. INDUSTRY SWOT ANALYSIS
C.1 Strengths to Build Upon
C.2 Weaknesses to Overcome
C.3 Opportunities to Exploit
C.4 Threats to Overcome
D. LOOKING AT AUROBINDO PHARMA
D.1 Company Profile
D.2 History of the Company
D.3 Aurobindo Pharma and the COVID-19 Pandemic
D.4 Ownership Pattern in the Company
D.5 Organizational Divisions
D.6 Profiling the Key Executives
D.7 Products & Services
E. AUROBINDO PHARMA: LOOKING AT BUSINESS
E.1 Business Segments
E.2 Company Strategy
E.3 Investment Analysis
E.4 Product Pipeline
E.5 Geographical Segments
E.6 Company Subsidiaries
F. AUROBINDO PHARMA: SWOT FRAMEWORK ANALYSIS
F.1 Strengths to Build Upon
F.2 Weaknesses to Overcome
F.3 Opportunities to Exploit
F.4 Threats to Overcome
G. PROFILING THE COMPETITION
G.1 Dr. Reddy's Laboratories Limited
##G.1.1 Corporate Profile
##G.1.2 Business Segment Analysis
##G.1.3 Financial Analysis
##G.1.4 SWOT Analysis
G.2 Cipla Limited
##G.2.1 Corporate Analysis
##G.2.2 Business Segment Analysis
##G.2.3 Financial Analysis
##G.2.4 SWOT Analysis
G.3 Pfizer
##G.3.1 Corporate Analysis
##G.3.2 Business Segment Analysis
##G.3.3 Financial Analysis
##G.3.4 SWOT Analysis
G.4 Sun Pharmaceutical Industries
H. AUROBINDO PHARMA: FINANCIAL ANALYSIS
H.1 Current Financials
H.2 Balance Sheet
H.3 Profit & Loss Statement
H.4 Ratio Analysis
##H.4.1 Annual Ratios
##H.4.2 Interim Ratios
##H.4.2 Capital Market Ratios
##H.4.3 Liquidity Ratios
I. GLOSSARY OF TERMS
